AMAhmed Marwan

Ahmed Marwan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ahmed Marwan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Ahmed Abdallah Salman

    Internal Medicine Department, Faculty of Medicine Cairo University Cairo Egypt

    1 shared publication
  • Ahmed E Taha

    Department of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, Cairo, Egypt

    1 shared publication
  • Ahmed Elewa

    General Surgery Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt

    1 shared publication
  • Ahmed Safina Abdallah

    General Surgery Department, Faculty of Medicine, Cairo University, Cairo, Egypt

    1 shared publication
  • Ahmed Youssef

    Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt

    1 shared publication
  • Asmaa Awwad

    Radiation Oncology and Nuclear Medicine Department, National Cancer Institute, Cairo University, Cairo, Egypt

    1 shared publication

Latest Publications

  • Open Access

    Effect of Roux-En-Y Gastric Bypass on Albuminuria in Morbidly Obese Patients with Type-2 Diabetes Mellitus: A Prospective Non-Randomized Controlled Study with 15-Month Follow-Up

    by Ahmed Abdallah Salman, Mohamed Abdalla Salman, Ahmed E Taha, Asmaa Awwad, Ahmed Marwan, Ahmed Elewa, Mona Yousry, Ahmed Safina Abdallah, Ahmed Youssef

    Background: Obesity increases the risk of chronic kidney disease and has been linked to proteinuria and albuminuria. Roux-en-Y gastric bypass (RYGB) plays a significant role in the treatment of obesity and type-2 diabetes mellitus (T2DM). This study aimed to examine the effect of RYGB on albuminuria in patients with morbid obesity and T2DM. Methods: This prospective, non-randomized, controlled study included two groups of patients with morbid obesity and T2DM; allocation was by patient preference rather than randomization. The RYGB Group (n = 64) underwent RYGB, and the Control Group (n = 58) received conservative (lifestyle) measures only. Micro- and macroalbuminuria were determined from spot urine albumin-to-creatinine ratio (uACR) on a first-morning urine sample. Patients were monitored for 15 months for remission and improvement of albuminuria. Groups were compared using the independent-sample t-test, Mann–Whitney test, or chi-square test as appropriate, and multivariable logistic regression was used to adjust for baseline differences. Results: The groups differed significantly at baseline in age, body mass index (BMI), HOMA-IR index, LDL-cholesterol, and ALT. RYGB achieved a significantly (p < 0.001) greater rate of albuminuria remission (57.8%) than diet control (24.1%). None of the baseline characteristics were associated with albuminuria remission except lower baseline triglyceride (p = 0.012) and LDL-cholesterol (p = 0.040) levels. Albuminuria remission was associated with significantly greater weight loss (p = 0.003) and lower BMI (p = 0.019), fasting plasma insulin (p = 0.014), HOMA-IR (p = 0.011), total cholesterol (p = 0.026), LDL-cholesterol (p = 0.001), ALT (p = 0.033), and AST (p = 0.009). After adjustment for baseline differences, RYGB remained the only independent predictor of albuminuria remission (adjusted odds ratio 3.27, 95% CI 1.23– 8.67; p = 0.017). Conclusion: In this non-randomized cohort, RYGB was associated with a significantly higher rate of albuminuria remission than lifestyle intervention over 15 months. Remission was associated with greater weight loss, lower plasma insulin, and improved insulin sensitivity rather than with diabetes remission itself. Randomized or better-adjusted prospective studies are warranted to confirm these findings.

  • Open Access

    Conference recommendations on immunosuppression practice for adult liver transplantation in Egypt

    by Nahed A Makhlouf, Iman F Montasser, Rasha Refaie, Yasmine M Massoud, Ahmed Marwan, Ehab Abdel-Khalek, Hadeel Gamal Eldeen, Mohamad EL Tabbakh, Mohamed Said, Wahid Doss, et al.

    Background: Adult living donor liver transplantation (LDLT) started in Egypt in 2001, with more than 5000 cases transplanted since then. In Egypt using only ABO compatible donor is the practice in all cases, and up till now, the only oncological indication for LDLT is hepatocellular carcinoma (HCC). The optimal management of the transplant recipient relies on understanding and proper utilization of immunosuppression regimens. The clinician should be aware of how to maintain the delicate balance between under-immunosuppression, leading to graft rejection, and over-immunosuppression, leading to the consequences of immunodeficiency such as sepsis and malignancy. The aim of this consensus is to provide clinical guidance to transplant physicians, transplant surgeons, clinical pharmacologists and nurses about immunosuppression in LDLT recipients. Main body: These national recommendations on immunosuppression in adult LDLT were developed by an experience exchange between the 22 centers currently undergoing LDLT in Egypt. A group of experts in liver transplantation from all over Egypt participated in the review of literature for different aspects related to these recommendations and, then they shared in formulation of several statements. In the United Conference on Hepato-gastroenterology and Infectious Diseases (UCHID) (2022), voting on these statements was done. Conclusion: Comprehensive national guidance is provided regarding the general principles of liver transplant immunosuppression, types of immunosuppression (IS), established IS drugs, types of rejection and their management, treatment of special groups, immunosuppression minimization, immune tolerance and complete IS withdrawal and the role of liver biopsy in orchestrating immunosuppression.